REALFLIGHT 7.5 PROMETHEUS SKIN

For members who have previously received a biologic or targeted synthetic DMARD indicated for moderately to severely active articular juvenile idiopathic arthritis or.Moderately to severely active articular juvenile idiopathic arthritis (JIA).Member has an intolerance or contraindication to methotrexate (see Appendix A).Member has experienced an inadequate response to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to 20 mg/week) or.C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) and.Member has been tested for all of the following biomarkers: Anti-cyclic citrullinated peptide (anti-CCP) or.Member has been tested for either of the following biomarkers and the test was positive: Member meets either of the following criteria: For treatment of moderately to severely active RA when all of the following criteria are met:.

For members who have previously received a biologic or targeted synthetic DMARD (e.g., Rinvoq, Xeljanz) indicated for moderately to severely active rheumatoid arthritis or.Moderately to severely active rheumatoid arthritis (RA).

REALFLIGHT 7.5 PROMETHEUS SKIN

For precertification of adalimumab (Humira), call (866) 752-7021 (Commercial), (866) 503-0857 (Medicare), or fax (866) 267-3277.ДЄetna considers adalimumab (Humira) medically necessary for the following indications where the member has a documented negative TB test (which can include a tuberculosis skin test (PPD), an interferon-release assay (IGRA), or a chest x-ray) Footnote1* within 6 months of initiating therapy for persons who are naive to biologic DMARDs or targeted synthetic DMARDs associated with an increased risk of TB, and repeated yearly for members with risk factors Footnote2** for TB that are continuing therapy with biologics: Precertification of adalimumab (Humira) is required of all Aetna participating providers and members in applicable plan designs.

Realflight 7.5 prometheus